BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy

BRAF and MEK inhibitors (BRAFi/MEKi), the standard treatment for patients with BRAF mutated melanoma, are currently explored in combination with various immunotherapies, notably checkpoint inhibitors and adoptive transfer of receptor-transfected T cells. Since two BRAFi/MEKi combinations with simila...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of molecular sciences Vol. 19; no. 1; p. 289
Main Authors:	Dörrie, Jan, Babalija, Lek, Hoyer, Stefanie, Gerer, Kerstin F, Schuler, Gerold, Heinzerling, Lucie, Schaft, Niels
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 18-01-2018 MDPI
Subjects:	Adoptive transfer Antigens BRAF inhibitor CAR-T cell CD25 antigen CD69 antigen CD8 antigen Cell activation Chimeric antigen receptors cobimetinib dabrafenib Immune checkpoint Immune system Immunotherapy Inhibitors kinase inhibitor Lymphocytes Lymphocytes T MEK inhibitor MEK inhibitors Melanoma T cell receptors Targeted cancer therapy trametinib vemurafenib trametinib kinase inhibitor immunotherapy vemurafenib BRAF inhibitor melanoma MEK inhibitor cobimetinib CAR-T cell dabrafenib
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!